LianBio (LIAN)
| Market Cap | 1.06B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -294.97M |
| Shares Out | 105.26M |
| EPS (ttm) | -2.80 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 590,570 |
| Open | 10.31 |
| Previous Close | 10.31 |
| Day's Range | 8.74 - 10.31 |
| 52-Week Range | 8.74 - 16.37 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About LIAN
LianBio is a global, science-driven biopharmaceutical company dedicated to developing and commercializing innovative medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets. We have purposefully designed our organization to successfully execute on our vision by identifying, sourcing, developing and commercializing product candidates and partnering with highly innovative biopharmaceutical companies around the world. We are establishing an international infrastructure...
News
LianBio Announces Pricing of Initial Public Offering
SHANGHAI, China and PRINCETON, N.J., Oct. 31, 2021 (GLOBE NEWSWIRE) -- LianBio, a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, tod...
LianBio Announces Launch of Initial Public Offering
LianBio, a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the launch of its proposed initial public offering of its ...
LianBio IPO Registration Document (S-1)
LianBio has filed to go public with an IPO on the NASDAQ.